Wolfe Research analyst Alex Zukin maintains Salesforce (NYSE:CRM) with a Outperform and lowers the price target from $200 to $180.
Here’s How Much $100 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 10 years by 8.15% on an annualized basis producing an average annual return of 19.8%. Currently, Edwards Lifesciences has a market capitalization of $62.66 billion.
